Long-term Effectiveness of a Recombinant Hepatitis E Vaccine

Sponsor
Xiamen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05976594
Collaborator
Dongtai Center for Disease Control and Prevention (Other), Dongtai Hospital of Traditional Chinese Medicine (Other), Dongtai People's Hospital (Other)
5,800
1
22.5
257.3

Study Details

Study Description

Brief Summary

This test-negative study is designed to evaluate the long-term effectiveness of hepatitis E vaccine (Hecolin®) and to explore the prevalence of rat hepatitis E in Dongtai City.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: serology and virology detection of hepatitis E virus

Detailed Description

In this negative test study, residual clinical serum will be collected from 13 hospitals in Dongtai, if it was from patients born between 1941-1991 from 11 towns in Dongtai, who tested positive for ALT levels higher than 2.5 times the upper limit of normal (ULN). Detection of HEV IgM, IgG, antigen, RNA will be performed to diagnose hepatitis E (HE) in each individual. In addition, HE vaccination history will be collect. All the information above will be used to evaluate the long-term effectiveness of HE vaccine. Based on the study design, virological and serological detection (IgM, IgG, antigen, and RNA) of hepatitis E virus species C (HEV-C) will be performed to analyze the prevalence of rat hepatitis E infection in Dongtai.

Study Design

Study Type:
Observational
Anticipated Enrollment :
5800 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine: a Test-negative Design Study
Anticipated Study Start Date :
Aug 15, 2023
Anticipated Primary Completion Date :
Jul 1, 2025
Anticipated Study Completion Date :
Jul 1, 2025

Arms and Interventions

Arm Intervention/Treatment
HE group

Subjects who has been diagnosed as HE.

Diagnostic Test: serology and virology detection of hepatitis E virus
Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C),and further HEV genotyping for those positive for HEV-RNA.

Control group

Subjects who didn't meet the diagnosis criteria of HE.

Diagnostic Test: serology and virology detection of hepatitis E virus
Serum will be tested for HEV serology and virology, including HEV-IgM, HEV-IgG, HEV-antigen, and HEV-RNA for HEV species A (HEV-A) and HEV species C (HEV-C),and further HEV genotyping for those positive for HEV-RNA.

Outcome Measures

Primary Outcome Measures

  1. Rate of hepatitis E infection [Two months after sampling]

    In patients with ALT > 2.5 ULN, HEV infection is diagnosed as positive when two of the following indicators are positive: (1) HEV-IgM; (2) Seroconversion or four-fold increase of HEV-IgG;(3) HEV-RNA; (4) HEV-antigen.

Secondary Outcome Measures

  1. Rate of rat hepatitis E infection [Two months after sampling]

    In patients with ALT > 2.5 ULN, rat hepatitis E infection is diagnosed as positive when two of the following virologic or serological tests are positive: (1) IgM anti-HEV-C-; (2) IgG anti-HEV-C- seroconversion or four-fold increase;(3) HEV-C-RNA; (4) HEV-C-antigen.

Eligibility Criteria

Criteria

Ages Eligible for Study:
32 Years to 82 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. From 11 townships(Anfeng、Fuan、Tangyang、Hougang、Liangduo、Qingdong、Shiyan、Shenzao、Wulie、Xuhe、Xin jie)

  2. ALT ≥ 2.5 ULN

  3. Born between 1941 and 1991

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dongtai Center for Disease Control and Prevention Dongtai Jiangsu China 224200

Sponsors and Collaborators

  • Xiamen University
  • Dongtai Center for Disease Control and Prevention
  • Dongtai Hospital of Traditional Chinese Medicine
  • Dongtai People's Hospital

Investigators

  • Study Director: Zhang Jun, M.D., National Institute of Diagnostics and Vaccine Development in infectious disease, Xiamen University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jun Zhang, professor, Xiamen University
ClinicalTrials.gov Identifier:
NCT05976594
Other Study ID Numbers:
  • PRO-HE-004-2
First Posted:
Aug 4, 2023
Last Update Posted:
Aug 4, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jun Zhang, professor, Xiamen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 4, 2023